What is the current valuation of the Immuno-Oncology Market as of 2024?

The Immuno-Oncology Market was valued at 125.69 USD Billion in 2024. Read More

What is the projected market size for the Immuno-Oncology Market by 2035?

The market is projected to reach 333.7 USD Billion by 2035. Read More

What is the expected CAGR for the Immuno-Oncology Market during the forecast period 2025 - 2035?

The expected CAGR for the Immuno-Oncology Market during 2025 - 2035 is 9.28%. Read More

Which cancer types are leading in market valuation within the Immuno-Oncology sector?

Lung Cancer and Breast Cancer are leading, with valuations of 30.0 to 80.0 USD Billion and 25.0 to 70.0 USD Billion, respectively. Read More

What are the key treatment modalities driving the Immuno-Oncology Market?

Checkpoint Inhibitors dominate the market, with a valuation range of 45.0 to 120.0 USD Billion. Read More

How do combination therapies impact the Immuno-Oncology Market?

Combination therapies, particularly Targeted Therapy Combinations, are projected to reach 50.69 to 138.7 USD Billion. Read More

Which biomarkers are most significant in the Immuno-Oncology Market?

PD-L1 and PD-1 are significant biomarkers, with valuations ranging from 30.0 to 80.0 USD Billion and 25.0 to 70.0 USD Billion, respectively. Read More

What role do key players like Bristol-Myers Squibb and Merck & Co. play in the market?

Key players such as Bristol-Myers Squibb and Merck & Co. are instrumental in driving innovation and market growth. Read More

What is the market outlook for advanced stage cancer treatments in Immuno-Oncology?

Advanced stage cancer treatments are expected to grow significantly, with a projected valuation of 50.0 to 130.0 USD Billion. Read More

How does the Immuno-Oncology Market compare across different disease stages?

The market shows a strong focus on advanced and metastatic disease stages, with valuations of 50.0 to 130.0 USD Billion and 50.69 to 133.7 USD Billion, respectively. Read More

Immuno Oncology Market

Immuno-Oncology Market Research Report: Size, Share, Trend Analysis By Cancer Type (Lung Cancer, Melanoma, Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma), By Treatment Modality (Checkpoint Inhibitors, Adoptive Cell Therapy, Cancer Vaccines, Oncolytic Viruses, Targeted Therapies), By Biomarker Type (PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, IDO), By Combination Therapies (Checkpoint Inhibitor Combinations, Checkpoint Inhibitors and Targeted Therapies, Checkpoint Inhibitors and Immunotherapy, Targeted Therapy Combinations), By Disease Stage (Early Stage, Advanced Stage, Metastatic Disease) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

9.28%

2024 Market Size

$ 125.69 Billion

2035 Market Size

$ 333.7 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/35962-HCR | Pages: 100 | Author: Nidhi Mandole, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Cancer Type (USD Billion) | |
  1. 4.1.1 Lung Cancer | |
  2. 4.1.2 Melanoma | |
  3. 4.1.3 Breast Cancer | |
  4. 4.1.4 Colorectal Cancer | |
  5. 4.1.5 Leukemia | |
  6. 4.1.6 Lymphoma |
2. 4.2 Healthcare, BY Treatment Modality (USD Billion) | |
  1. 4.2.1 Checkpoint Inhibitors | |
  2. 4.2.2 Adoptive Cell Therapy | |
  3. 4.2.3 Cancer Vaccines | |
  4. 4.2.4 Oncolytic Viruses | |
  5. 4.2.5 Targeted Therapies |
3. 4.3 Healthcare, BY Biomarker Type (USD Billion) | |
  1. 4.3.1 PD-1 | |
  2. 4.3.2 PD-L1 | |
  3. 4.3.3 CTLA-4 | |
  4. 4.3.4 LAG-3 | |
  5. 4.3.5 TIM-3 | |
  6. 4.3.6 IDO |
4. 4.4 Healthcare, BY Combination Therapies (USD Billion) | |
  1. 4.4.1 Checkpoint Inhibitor Combinations | |
  2. 4.4.2 Checkpoint Inhibitors and Targeted Therapies | |
  3. 4.4.3 Checkpoint Inhibitors and Immunotherapy | |
  4. 4.4.4 Targeted Therapy Combinations |
5. 4.5 Healthcare, BY Disease Stage (USD Billion) | |
  1. 4.5.1 Early Stage | |
  2. 4.5.2 Advanced Stage | |
  3. 4.5.3 Metastatic Disease |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Bristol-Myers Squibb (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Merck & Co. (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Roche (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 AstraZeneca (GB) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Novartis (CH) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Pfizer (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Gilead Sciences (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Eli Lilly and Company (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Amgen (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY CANCER TYPE |
7. 6.4 US MARKET ANALYSIS BY TREATMENT MODALITY |
8. 6.5 US MARKET ANALYSIS BY BIOMARKER TYPE |
9. 6.6 US MARKET ANALYSIS BY COMBINATION THERAPIES |
10. 6.7 US MARKET ANALYSIS BY DISEASE STAGE |
11. 6.8 CANADA MARKET ANALYSIS BY CANCER TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY TREATMENT MODALITY |
13. 6.10 CANADA MARKET ANALYSIS BY BIOMARKER TYPE |
14. 6.11 CANADA MARKET ANALYSIS BY COMBINATION THERAPIES |
15. 6.12 CANADA MARKET ANALYSIS BY DISEASE STAGE |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY CANCER TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY TREATMENT MODALITY |
19. 6.16 GERMANY MARKET ANALYSIS BY BIOMARKER TYPE |
20. 6.17 GERMANY MARKET ANALYSIS BY COMBINATION THERAPIES |
21. 6.18 GERMANY MARKET ANALYSIS BY DISEASE STAGE |
22. 6.19 UK MARKET ANALYSIS BY CANCER TYPE |
23. 6.20 UK MARKET ANALYSIS BY TREATMENT MODALITY |
24. 6.21 UK MARKET ANALYSIS BY BIOMARKER TYPE |
25. 6.22 UK MARKET ANALYSIS BY COMBINATION THERAPIES |
26. 6.23 UK MARKET ANALYSIS BY DISEASE STAGE |
27. 6.24 FRANCE MARKET ANALYSIS BY CANCER TYPE |
28. 6.25 FRANCE MARKET ANALYSIS BY TREATMENT MODALITY |
29. 6.26 FRANCE MARKET ANALYSIS BY BIOMARKER TYPE |
30. 6.27 FRANCE MARKET ANALYSIS BY COMBINATION THERAPIES |
31. 6.28 FRANCE MARKET ANALYSIS BY DISEASE STAGE |
32. 6.29 RUSSIA MARKET ANALYSIS BY CANCER TYPE |
33. 6.30 RUSSIA MARKET ANALYSIS BY TREATMENT MODALITY |
34. 6.31 RUSSIA MARKET ANALYSIS BY BIOMARKER TYPE |
35. 6.32 RUSSIA MARKET ANALYSIS BY COMBINATION THERAPIES |
36. 6.33 RUSSIA MARKET ANALYSIS BY DISEASE STAGE |
37. 6.34 ITALY MARKET ANALYSIS BY CANCER TYPE |
38. 6.35 ITALY MARKET ANALYSIS BY TREATMENT MODALITY |
39. 6.36 ITALY MARKET ANALYSIS BY BIOMARKER TYPE |
40. 6.37 ITALY MARKET ANALYSIS BY COMBINATION THERAPIES |
41. 6.38 ITALY MARKET ANALYSIS BY DISEASE STAGE |
42. 6.39 SPAIN MARKET ANALYSIS BY CANCER TYPE |
43. 6.40 SPAIN MARKET ANALYSIS BY TREATMENT MODALITY |
44. 6.41 SPAIN MARKET ANALYSIS BY BIOMARKER TYPE |
45. 6.42 SPAIN MARKET ANALYSIS BY COMBINATION THERAPIES |
46. 6.43 SPAIN MARKET ANALYSIS BY DISEASE STAGE |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY CANCER TYPE |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY TREATMENT MODALITY |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY BIOMARKER TYPE |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY COMBINATION THERAPIES |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY DISEASE STAGE |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY CANCER TYPE |
54. 6.51 CHINA MARKET ANALYSIS BY TREATMENT MODALITY |
55. 6.52 CHINA MARKET ANALYSIS BY BIOMARKER TYPE |
56. 6.53 CHINA MARKET ANALYSIS BY COMBINATION THERAPIES |
57. 6.54 CHINA MARKET ANALYSIS BY DISEASE STAGE |
58. 6.55 INDIA MARKET ANALYSIS BY CANCER TYPE |
59. 6.56 INDIA MARKET ANALYSIS BY TREATMENT MODALITY |
60. 6.57 INDIA MARKET ANALYSIS BY BIOMARKER TYPE |
61. 6.58 INDIA MARKET ANALYSIS BY COMBINATION THERAPIES |
62. 6.59 INDIA MARKET ANALYSIS BY DISEASE STAGE |
63. 6.60 JAPAN MARKET ANALYSIS BY CANCER TYPE |
64. 6.61 JAPAN MARKET ANALYSIS BY TREATMENT MODALITY |
65. 6.62 JAPAN MARKET ANALYSIS BY BIOMARKER TYPE |
66. 6.63 JAPAN MARKET ANALYSIS BY COMBINATION THERAPIES |
67. 6.64 JAPAN MARKET ANALYSIS BY DISEASE STAGE |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY CANCER TYPE |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY TREATMENT MODALITY |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY BIOMARKER TYPE |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY COMBINATION THERAPIES |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY DISEASE STAGE |
73. 6.70 MALAYSIA MARKET ANALYSIS BY CANCER TYPE |
74. 6.71 MALAYSIA MARKET ANALYSIS BY TREATMENT MODALITY |
75. 6.72 MALAYSIA MARKET ANALYSIS BY BIOMARKER TYPE |
76. 6.73 MALAYSIA MARKET ANALYSIS BY COMBINATION THERAPIES |
77. 6.74 MALAYSIA MARKET ANALYSIS BY DISEASE STAGE |
78. 6.75 THAILAND MARKET ANALYSIS BY CANCER TYPE |
79. 6.76 THAILAND MARKET ANALYSIS BY TREATMENT MODALITY |
80. 6.77 THAILAND MARKET ANALYSIS BY BIOMARKER TYPE |
81. 6.78 THAILAND MARKET ANALYSIS BY COMBINATION THERAPIES |
82. 6.79 THAILAND MARKET ANALYSIS BY DISEASE STAGE |
83. 6.80 INDONESIA MARKET ANALYSIS BY CANCER TYPE |
84. 6.81 INDONESIA MARKET ANALYSIS BY TREATMENT MODALITY |
85. 6.82 INDONESIA MARKET ANALYSIS BY BIOMARKER TYPE |
86. 6.83 INDONESIA MARKET ANALYSIS BY COMBINATION THERAPIES |
87. 6.84 INDONESIA MARKET ANALYSIS BY DISEASE STAGE |
88. 6.85 REST OF APAC MARKET ANALYSIS BY CANCER TYPE |
89. 6.86 REST OF APAC MARKET ANALYSIS BY TREATMENT MODALITY |
90. 6.87 REST OF APAC MARKET ANALYSIS BY BIOMARKER TYPE |
91. 6.88 REST OF APAC MARKET ANALYSIS BY COMBINATION THERAPIES |
92. 6.89 REST OF APAC MARKET ANALYSIS BY DISEASE STAGE |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY CANCER TYPE |
95. 6.92 BRAZIL MARKET ANALYSIS BY TREATMENT MODALITY |
96. 6.93 BRAZIL MARKET ANALYSIS BY BIOMARKER TYPE |
97. 6.94 BRAZIL MARKET ANALYSIS BY COMBINATION THERAPIES |
98. 6.95 BRAZIL MARKET ANALYSIS BY DISEASE STAGE |
99. 6.96 MEXICO MARKET ANALYSIS BY CANCER TYPE |
100. 6.97 MEXICO MARKET ANALYSIS BY TREATMENT MODALITY |
101. 6.98 MEXICO MARKET ANALYSIS BY BIOMARKER TYPE |
102. 6.99 MEXICO MARKET ANALYSIS BY COMBINATION THERAPIES |
103. 6.100 MEXICO MARKET ANALYSIS BY DISEASE STAGE |
104. 6.101 ARGENTINA MARKET ANALYSIS BY CANCER TYPE |
105. 6.102 ARGENTINA MARKET ANALYSIS BY TREATMENT MODALITY |
106. 6.103 ARGENTINA MARKET ANALYSIS BY BIOMARKER TYPE |
107. 6.104 ARGENTINA MARKET ANALYSIS BY COMBINATION THERAPIES |
108. 6.105 ARGENTINA MARKET ANALYSIS BY DISEASE STAGE |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY CANCER TYPE |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT MODALITY |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY BIOMARKER TYPE |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY COMBINATION THERAPIES |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE STAGE |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY CANCER TYPE |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT MODALITY |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY BIOMARKER TYPE |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY COMBINATION THERAPIES |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY DISEASE STAGE |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY CANCER TYPE |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT MODALITY |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY BIOMARKER TYPE |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY COMBINATION THERAPIES |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY DISEASE STAGE |
125. 6.122 REST OF MEA MARKET ANALYSIS BY CANCER TYPE |
126. 6.123 REST OF MEA MARKET ANALYSIS BY TREATMENT MODALITY |
127. 6.124 REST OF MEA MARKET ANALYSIS BY BIOMARKER TYPE |
128. 6.125 REST OF MEA MARKET ANALYSIS BY COMBINATION THERAPIES |
129. 6.126 REST OF MEA MARKET ANALYSIS BY DISEASE STAGE |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY CANCER TYPE, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY CANCER TYPE, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY TREATMENT MODALITY, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY TREATMENT MODALITY, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY BIOMARKER TYPE, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY BIOMARKER TYPE, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY COMBINATION THERAPIES, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY COMBINATION THERAPIES, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY DISEASE STAGE, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY DISEASE STAGE, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY CANCER TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY TREATMENT MODALITY, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY BIOMARKER TYPE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY COMBINATION THERAPIES, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY DISEASE STAGE, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Immuno Oncology Market Segmentation

Immuno Oncology Market By Cancer Type (USD Billion, 2025-2035)

Lung Cancer
Melanoma
Breast Cancer
Colorectal Cancer
Leukemia
Lymphoma

Immuno Oncology Market By Treatment Modality (USD Billion, 2025-2035)

Checkpoint Inhibitors
Adoptive Cell Therapy
Cancer Vaccines
Oncolytic Viruses
Targeted Therapies

Immuno Oncology Market By Biomarker Type (USD Billion, 2025-2035)

PD-1
PD-L1
CTLA-4
LAG-3
TIM-3
IDO

Immuno Oncology Market By Combination Therapies (USD Billion, 2025-2035)

Checkpoint Inhibitor Combinations
Checkpoint Inhibitors and Targeted Therapies
Checkpoint Inhibitors and Immunotherapy
Targeted Therapy Combinations

Immuno Oncology Market By Disease Stage (USD Billion, 2025-2035)

Early Stage
Advanced Stage
Metastatic Disease

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”